OKYO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OKYO Pharma Ltd is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks immediate positive catalysts, has bearish technical indicators, and no significant trading signals. While analysts are optimistic about the company's lead asset, the lack of recent financial data, news, or strong trading trends makes it prudent to hold off on investing at this time.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 36.941, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key support is at 1.527, with resistance at 1.703. Overall, the technical indicators suggest a bearish trend.
Analyst from Piper Sandler initiated coverage with an Overweight rating and a $7 price target, citing meaningful efficacy and safety data for the company's lead asset, urcosimod, addressing an unmet medical need.
No significant trading trends from hedge funds or insiders. No recent news or congress trading data. Bearish technical indicators and lack of financial performance data.
No financial data available for assessment.
Piper Sandler analyst Biren Amin initiated coverage with an Overweight rating and a $7 price target. The analyst is positive on the company's lead asset, urcosimod, for treating neuropathic corneal pain, citing meaningful efficacy and safety data.
